Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker ... the Tokyo-based company is focused neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...